Abstract: Described herein are compositions and methods for the prevention and treatment of ebolavirus infection certain embodiments of the present invention, monoclonal antibodies substantially similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.

Abstract: Described herein are compositions and methods for the prevention and treatment of ebolavirus infection. In certain embodiments of the present invention, monoclonal antibodies substantially, similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.

Abstract: Described herein are compositions and methods for the prevention and treatment of ebolavirus infection. In certain embodiments of the present invention, monoclonal antibodies substantially similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.

Abstract: Described herein are compositions and methods for the prevention and treatment of ebolavirus infection. In certain embodiments of the present invention, monoclonal antibodies substantially similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.

Abstract: Described herein are compositions and methods for the prevention and treatment of ebolavirus infection. In certain embodiments of the present invention, monoclonal antibodies substantially similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.

Abstract: Described herein are compositions and methods for the prevention and treatment of ebolavirus infection. In certain embodiments of the present invention, monoclonal antibodies substantially, similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.

Abstract: Disclosed are bispecific antibodies and bispecific fission constructs that bind to Niemann-Pick C1 (NPC1) receptor for treating or preventing filovirus infections, pharmaceutical compositions comprising the bispecific antibodies, and therapeutic methods using the bispecific antibodies.

Abstract: Methods and systems for modifying network traffic data. The method of modifying network traffic may include receiving a network traffic data unit that includes an identifier, at a proxy port; based on the identifier, performing a proxy port action set to obtain a modified network traffic data unit; and transmitting the modified network traffic data unit towards an egress port.

Abstract: The present invention addresses a need for improved treatments for filovirus infections. This invention provides an isolated humanized anti-filovirus glycoprotein pre-fusion core antibody comprising a framework region having a sequence of 95% or greater identity to a human antibody framework region. Also provided is a method of treating and/or inhibiting a filovirus infection in a subject comprising administering to the subject an amount of any of the antibodies described herein, or an amount of an antigen-binding fragment thereof. Also provided is composition comprising any of the antibodies described herein, or or an amount of an antigen-binding fragment thereof. In an embodiment, the composition comprises a pharmaceutically acceptably carrier.

Abstract: The present invention is related to the development of therapeutics and prophylactics for the treatment and/or prevention of filovirus infection in humans and other mammals. A new class of small molecules is disclosed that inhibits the interaction of naturally processed (i.e., proteolytically cleaved) filovirus glycoprotein (GPCL) with its host receptor Niemann-Pick C1 (NPC1) protein and thus block infection of host cells by filoviruses. Also disclosed are methods of using the small molecule inhibitors in the treatment/prevention of filovirus infection.

Abstract: Disclosed are bispecific antibodies and bispecific fusion constructs that bind to Niemann-Pick CI (NPC1) receptor for treating or preventing filovirus infections, pharmaceutical compositions comprising the bispecific antibodies, and therapeutic methods using the bispecific antibodies.

Abstract: Methods and systems for controlling a denitrification reaction in a biological nitrogen removal reactor including denitrifying bacteria to favor denitratation of nitrate to nitrite and limit denitritation of nitrite to nitrogen gas are disclosed. pH, dissolved oxygen levels, solids retention time, and chemical oxygen demand to nitrogen ratio are controlled to favor this reaction. Wastewater or contaminated groundwater including concentrations of ammonium and nitrate are continuously fed to the biological nitrogen removal reactor along with a source of carbon and electrons as an influent, which is treated to form a nitrite effluent. The nitrite effluent may then be fed to an anammox reactor including anammox bacteria for production of nitrogen gas. The system may be operated under substantially anoxic conditions, which provides significant cost savings without sacrificing efficiency or productivity compared to traditional wastewater treatment systems and processes.

Abstract: The present invention addresses a need for antibodies useful for filovirus infections.

Abstract: Methods and assays are disclosed for treating a subject with a hantavirus infection using an agent that binds to protocadherin-1 (PCDH1) or inhibits expression of protocadherin-1 (PCDH1).

Abstract: A method and apparatus of a network element that updates an interface list of a multi-link group of a network element is described. In an exemplary embodiment, a network element receives an indication that the interface list for the multi-link group on a network element is to change. In addition, the interface list includes a first set of interfaces. The network element further includes an address table having a plurality of address entries, where each of the plurality of address entries includes an address, a multi-link nexthop, and a tag group reference. The tag group reference references an entry in a tag group table, where a tag group entry includes a tag group identifier and a tag group set of interfaces. The network element further receives a second set of interfaces. The network element additionally updates the interface list for the tag group entry to include a second set of interfaces. Furthermore, the network element transmits data with the multi-link group using the second set of interfaces.

Abstract: Methods and systems for simultaneously enhancing the production of both methane and volatile fatty acids in an anaerobic digestion bioreactor are disclosed. In some embodiments, the methods include: providing a stream of organic feedstock; providing a plurality of anaerobic digester bioreactors, each of the plurality of anaerobic digester bioreactors connected in series; step-feeding predetermined percentages of the stream of organic feedstock to two or more of the plurality of anaerobic digester bioreactors; feeding effluent from each of the plurality of anaerobic digester bioreactors to a subsequent one of the plurality of anaerobic digester bioreactors; and anaerobically digesting at least one of the stream of organic feedstock and the effluent from each of the plurality of anaerobic digester bioreactors to develop a final effluent stream including methane and volatile fatty acids. The volatile fatty acids are then microbially converted to lipids in an aerobic bioreactor.

Abstract: The present invention addresses a need for improved treatments for Filovirus infections.

Abstract: Described herein are compositions and methods for the prevention and treatment of ebolavirus infection certain embodiments of the present invention, monoclonal antibodies substantially similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.

Abstract: Methods and systems for simultaneously enhancing the production of both methane and volatile fatty acids in an anaerobic digestion bioreactor are disclosed. In some embodiments, the methods include: providing a stream of organic feedstock; providing a plurality of anaerobic digester bioreactors, each of the plurality of anaerobic digester bioreactors connected in series; step-feeding predetermined percentages of the stream of organic feedstock to two or more of the plurality of anaerobic digester bioreactors; feeding effluent from each of the plurality of anaerobic digester bioreactors to a subsequent one of the plurality of anaerobic digester bioreactors; and anaerobically digesting at least one of the stream of organic feedstock and the effluent from each of the plurality of anaerobic digester bioreactors to develop a final effluent stream including methane and volatile fatty acids. The volatile fatty acids are then microbially converted to lipids in an aerobic bioreactor.

Abstract: Disclosed are bispecific antibodies and bispecific fusion constructs that bind to Niemann-Pick CI (NPC1) receptor for treating or preventing filovirus infections, pharmaceutical compositions comprising the bispecific antibodies, and therapeutic methods using the bispecific antibodies.